Navigation Links
Ansun BioPharma Announces Potent in-vitro DAS181 Activity against Respiratory Syncytial Virus at 5th Congress of Virology
Date:12/8/2015

SAN DIEGO, Dec. 8, 2015 /PRNewswire/ -- Ansun BioPharma announced preliminary data suggesting in-vitro activity of DAS181 against Respiratory Syncytial Virus (RSV), a virus which causes significant morbidity and mortality in patients. The data was presented at the 5th Congress of Virology in Atlanta, Georgia in a keynote address by Ronald Moss, MD, CEO of Ansun. The in-vitro inhibition against the virus was observed to be more potent than Ribavarin, the current treatment for RSV. "This is very important data as RSV is a common respiratory pathogen and additional treatments are needed," noted Dr. Moss. "As DAS181 is currently in the clinic being studied for the treatment of other respiratory viruses, clinical trials are warranted to test the efficacy of this drug against RSV infection as well," commented Dr. Moss.

About Ansun BioPharma

Ansun BioPharma is a clinical stage biopharmaceutical company focused on the development of unique host-directed anti-viral therapies for respiratory viruses.  DAS181 has two indications in late stage clinical development. FluDaseTM is a first-in-class broad-spectrum investigational therapeutic agent to treat all forms of influenza, including pandemic variants and drug-resistant variants that cannot be treated by any currently approved flu therapies, including H1N1, H5N1 and H7N9. ParaDaseTM is an investigational drug which is designed to target the receptor for parainfluenza viruses and is being evaluated in a Phase 2 trial for the treatment of severe parainfluenza infection in immunocompromised patients. ParaDaseTM has received Fast Track Designation by the U.S. FDA. Preclinical data suggests that DAS181 may have additional activity against other respiratory viruses. For more information, please visit www.ansunbiopharma.com or www.clinicaltrials.gov using the identifier NCT01644877.

 


'/>"/>
SOURCE Ansun BioPharma
Copyright©2015 PR Newswire.
All rights reserved


Related biology technology :

1. Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
2. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
3. Infinata Implements “Clear Quality” Initiative to Optimize Reliability and Usability of Data, Reports and Analysis for Biopharma and Wealth Management Solutions
4. Verified Clinical Trials (VCT) Will Co-Present With SAFE-BioPharma At Bio-IT World April 10th In Boston, MA Exploring Identity Management In eClinical Trials
5. DSM announces June opening of new cGMP biopharmaceutical manufacturing operation in Brisbane, Australia
6. Biotechnology Market (Biopharmacy, Bioservices, Bioagri, Bioindustrial) Is Expected to Reach USD 414.5 Billion Globally in 2017: Transparency Market Research
7. MannKind, Ariad Pharma, Ziopharm Oncology, Galena Biopharma, and Novavax Under StockCalls Microscope
8. Genedata Biologics for Biopharma R&D at Ninth Annual PEGS
9. PDL BioPharma Appoints Peter Garcia as Chief Financial Officer
10. Array BioPharma to Present at the Bank of America Merrill Lynch Healthcare Conference and the UBS Global Healthcare Conference
11. PDL BioPharma Announces First Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/11/2019)... ... June 10, 2019 , ... ... 80 of its scientific journals to DeepDyve’s rental service for peer-reviewed journals. ... expanding library of more than 20 million articles, sourced from more than 15,000 ...
(Date:6/6/2019)... (PRWEB) , ... June 05, 2019 , ... WCCT ... and medical device industries, announced today that they will be receiving 3 awards at ... Diego, CA. WCCT received 2 awards in the categories of overall Quality and Compatibility ...
(Date:5/31/2019)... ... May 30, 2019 , ... Object Pharma, Inc., a startup ... of Metabiologics, Inc., a globally recognized leader in the production and sale of ... to a full spectrum of botulinum neurotoxins, as well as a CDC approved ...
(Date:5/15/2019)... ... ... Milton Hershey School® has named William Charles Ballough Harding ’78 the 2019 Alumnus ... is changing lives by creating solutions to global healthcare challenges through the development of ... founders – Milton and Catherine Hershey – who always hoped for Milton Hershey School ...
Breaking Biology Technology:
(Date:6/4/2019)... SAN DIEGO (PRWEB) , ... June 04, 2019 , ... ... Hall of Fame recipients. The recognition, which honors hospitality excellence, is given only to ... a Certificate of Excellence for five consecutive years. , To qualify for ...
(Date:5/31/2019)... ... May 30, 2019 , ... Join Julie Peacock, Vice President ... on Wednesday, June 19, 2019 at 1pm EDT where she will demonstrate how ... teams and contract research organizations (CROs) can improve collaboration, auditing, document tracking and ...
(Date:5/23/2019)... ... May 23, 2019 , ... Federal Publications Seminars, the leading ... pleased to announce the release of FPSOnline 2.0, an updated version of its ... weeklong conferences , La Jolla Government Contracts Week, were given a “sneak peek” of ...
Breaking Biology News(10 mins):